The assessment of immunity against hepatitis B after vaccination

Frisch-Niggemeyer, W; Ambrosch, F; Hofmann, H

doi:10.1016/0092-1157(86)90011-9

Cited by 17 publications

(7 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whether the slight difference in antibody levels obtained is of practical importance is unknown. It is usual to consider anti-HBs plasma levels of 10 IU/l to have a protective effect [10,11]. In our groups all participants developed antibody levels greater than 10 IU/l.…”

Section: Discussionmentioning

confidence: 66%

Immunogenicity of yeast-derived hepatitis B vaccine from two different producers

Dahl-Hansen¹,

Siebke²,

Ss³

et al. 1990

Epidemiol. Infect.

View full text Add to dashboard Cite

SUMMARYThe immunogenicity and reactogenicity of two preparations of yeast-derived hepatitis B vaccines were compared in healthy adult populations. The two groups were vaccinated in parallel, but they were not matched for age and sex. All subjects seroconverted, and 9 months after the first vaccine dose, all had anti HBs titres of at least 10 IU/l. The anti-HBs titres were higher in the group of subjects given 20 gtg vaccine antigen made by Smith Kline & RIT (GMT 2943 at 9 months) compared to those who received 10 ,tg of vaccine made by Merck, Sharp & Dohme (GMT 729 at 9 months). Adverse effects were recorded in 32'0 and 44'7 % of the participants, but these were limited to minor local and general reactions. In the present study both preparations were safe and efficient.

show abstract

Section: Discussionmentioning

confidence: 66%

Immunogenicity of yeast-derived hepatitis B vaccine from two different producers

Dahl-Hansen¹,

Siebke²,

Ss³

et al. 1990

Epidemiol. Infect.

View full text Add to dashboard Cite

show abstract

“…The protective level threshold, ≥10 mIU/mL, did not originate from active immunization studies . This figure is based on the result of a passive immunization study from France, which was published in 1978 .…”

Section: Why Is the Anti‐hbs Level Of ≥10 Miu/ml Considered Protective?mentioning

confidence: 99%

“…Serum with an anti‐HBs ≥2.1 RU was considered seropositive. Conversion from RU to mIU/mL was estimated to be 2.1 RU = 9.9 mIU/mL . According to the conversion formula, the frequency of HBV infection was 11.11% and 0.23% in individuals whose anti‐HBs levels were 10–49 mIU/mL and ≥50 mIU/mL, respectively, after a three‐dose HB vaccination series.…”

Section: Why Is the Anti‐hbs Level Of ≥10 Miu/ml Considered Protective?mentioning

confidence: 99%

“…For three decades, serum anti‐HB surface antibody (HBs) levels of ≥10 mIU/mL have been considered to be values for which protection can be expected . The choice of “10 mIU/mL” as a threshold is the result of animal experiments and considerable practical experience in early studies . The data on which the choice of 10 mIU/mL might be based were never published …”

Section: Introductionmentioning

confidence: 99%

“…The choice of “10 mIU/mL” as a threshold is the result of animal experiments and considerable practical experience in early studies . The data on which the choice of 10 mIU/mL might be based were never published …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Discordance of hepatitis B vaccination policies for healthcare workers between the USA, the UK, and Germany

Komatsu

Klenerman

Thimme

2020

Hepatology Research

View full text Add to dashboard Cite

The hepatitis B (HB) vaccine is effective for the prevention of HB virus infection. It has been widely accepted that an anti‐HB surface antibody (HBs) level ≥10 mIU/mL is protective against HB virus infection. Although transient infection can occur in individuals who attain a peak level of anti‐HBs ≥10 mIU/mL after primary vaccination, long‐term follow‐up studies show that successful primary vaccination can prevent individuals from acute clinical hepatitis and chronic infection. Healthcare workers (HCWs) are at‐risk individuals. Based on the accumulated data, the USA considers an anti‐HBs level ≥10 mIU/mL to constitute successful vaccination for HCWs. In contrast, because some anti‐HBs assays cannot accurately measure in the low anti‐HBs range, including 10 mIU/mL, the UK and Germany consider an anti‐HBs level ≥100 mIU/mL to constitute successful vaccination for HCWs. In the USA and UK, a booster dose is unnecessary for HCWs after successful vaccination. In Germany, anti‐HBs testing is recommended for HCWs who are at particularly high individual exposure risk 10 years after successful primary immunization, and a booster dose is offered if the anti‐HBs level has declined to ˂100 mIU/mL. The differences in the goal of HB vaccination, reliability of anti‐HBs assays, and use of booster vaccination cause discordance in HB vaccination policies for HCWs.

show abstract

Enhanced chemiluminescence ELISA for the detection of antibody to hepatitis B virus surface antigen

Ireland¹,

Samuel²

1989

J. Biolumin. Chemilumin.

View full text Add to dashboard Cite

A chemiluminescent enzyme linked immunosorbent assay (ELISA) for the detection of antibody to hepatitis B virus surface antigen (anti-HBs) in human serum has been developed. Polystyrene microtitre plates were coated with recombinant, yeast-derived hepatitis B surface antigen (rec-HBsAg). Patient serum samples and appropriate controls were added to the rec-HBsAg-coated wells and incubated to bind anti-HBs. The wells were then washed and a fluorescein isothiocyanate (FITC) conjugate of a human plasma-derived hepatitis B surface antigen (HBsAg) was added. Following incubation and further washing, the bound FITC-labelled HBsAg was detected after addition of a horseradish peroxidase (HRP) conjugate of a monoclonal anti-FITC antibody and assaying for the enzyme. The activity of the HRP was measured using luminol and hydrogen peroxide as substrates and iodophenol as a chemiluminescence enhancer. The luminescence was recorded using a camera luminometer. Preliminary tests have shown the assay to be suitable for the detection of antibody in sera from both vaccinees and also from individuals with a past hepatitis B virus infection. The use of the FITC-anti-FITC system together with the measurement of a chemiluminescence signal makes possible the completion of this assay in a few hours. The assay has been shown to be both specific and sensitive and provides a permanent photographic record.

show abstract

The assessment of immunity against hepatitis B after vaccination

Cited by 17 publications

References 5 publications

Immunogenicity of yeast-derived hepatitis B vaccine from two different producers

Immunogenicity of yeast-derived hepatitis B vaccine from two different producers

Discordance of hepatitis B vaccination policies for healthcare workers between the USA, the UK, and Germany

Enhanced chemiluminescence ELISA for the detection of antibody to hepatitis B virus surface antigen

Contact Info

Product

Resources

About